Navigation Links
Santaris Pharma - Interim Report for the Period 1 January to 30 June 2009
Date:7/14/2009

ate to the effect that the Interim Report gives a true and fair view of the Company's assets and liabilities, financial position, results of operations and cash flows. Furthermore, we consider the Interim Report to give a true and fair statement of the developments in the Group's activities and financial affairs, results of operations and the Company's financial position as a whole as well as a description of the significant risks and uncertainties the Company faces.


    Board of Executives


        Soren Tulstrup      Henrik Stage

        President & CEO     Vice President & CFO


    Board of Directors


        Flemming         Walter         Claus          Soren Carlsen
        Ornskov          Wenninger      Braestrup

        Chairman         Vice Chairman  Director       Director



        Edwin de Graaf   Anders Hinsby  Martien van    Holger
                                        Osch           Reithinger

        Director         Director       Director       Director

Santaris Pharma forward looking statements

This written announcement contains forward-looking statements, identified by the use of words such as "believes," "expects," "may," "will," "should", "potential," "anticipates," "plans" or "intends" and similar expressions. Such forward-looking statements involve risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from the future results, events or developments indicated in this announcement. Such factors include, but are not limited to the timing, success and cost of clinical studies; the ability to obtain regulatory approval of products, market acceptance of and future demand for Santaris Pharma products and the impact of competitive products and pricing. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statemen
'/>"/>

SOURCE Santaris Pharma
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Santaris Pharma to Present at 10th Annual Biotechnology Industry Organisation CEO & Investor Conference - February 11th, 2008
2. Santaris Pharma Delivers Six LNA-Based RNA Inhibitors to Enzon Pharmaceuticals Ahead of Schedule
3. Santaris Pharma Director Appointed Adjunct Professor in RNA Biology at the University of Aalborg, Denmark
4. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
5. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
6. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
7. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
8. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
9. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 2014  RXi Pharmaceuticals Corporation (NASDAQ: ... on discovering, developing and commercializing innovative therapies ... technologies, today announced that their third Phase ... reduction of recurrence of hypertrophic scars following ... Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ...
(Date:7/30/2014)... 2014 Vala Sciences was recently ... Protection Agency (EPA). This new contract was awarded ... including tests designed to assess the effect of ... of connections between neurons (synapses), which are critical ... formation by environmental pollutants likely contributes to a ...
(Date:7/30/2014)... LayerBio, Inc., an MIT spinoff developing novel ... of seed financing from friends and family investors. Proceeds ... a novel sustained-release product for ophthalmology. , "We are ... commitment to this important work," said Dr. Ken Mandell, ... many areas in which innovations in drug delivery have ...
(Date:7/29/2014)... have hurdled a number of significant technological challenges ... observing technology originally created for the James Webb ... Investigator Harvey Moseley, a scientist at NASA,s Goddard ... that electrostatically actuated microshutter arrays that is, ... are as functional as the current technology,s magnetically ...
Breaking Biology Technology:RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 2RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 4RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 5U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 2U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 3Revolutionary microshutter technology hurdles significant challenges 2Revolutionary microshutter technology hurdles significant challenges 3Revolutionary microshutter technology hurdles significant challenges 4
... (OTCQB: AHRO) ("AtheroNova"), a biotech company focused on the research ... that it has appointed Johan M. (Thijs) Spoor as a ... effective January 3, 2012. Mr. Spoor is an independent director ... the Board. "I am very pleased to ...
... Inc., has initiated its transition from technology development ... Stan Rose, Ph.D., as the company,s first chief ... Sklar, M.D., Ph.D., has agreed to join the ... pioneering the development of a novel technology with ...
... Jan. 5, 2012  ZyGEM Corp. Ltd., a developer ... of DNA and other nucleic acids, and the ... (USAMRIID), today announced the signing of a Cooperative ... of simplified sample processing solutions for biothreat agents. ...
Cached Biology Technology:AtheroNova Announces a New Board Member 2AtheroNova Announces a New Board Member 3Nabsys Expands Leadership Team to Prepare for Commercialization of Novel DNA Positional Sequencing Technology 2Nabsys Expands Leadership Team to Prepare for Commercialization of Novel DNA Positional Sequencing Technology 3Nabsys Expands Leadership Team to Prepare for Commercialization of Novel DNA Positional Sequencing Technology 4ZyGEM and USAMRIID Sign CRADA for Development of Simplified Sample Processing Solutions for Biothreat Agents 2ZyGEM and USAMRIID Sign CRADA for Development of Simplified Sample Processing Solutions for Biothreat Agents 3
(Date:7/29/2014)... Achalasia is a rare disease it affects 1 in ... in the esophageal wall. While its cause remains unknown, a ... in Belgium, the University of Bonn in Germany and other ... autoimmune in origin. The study, published on 6 July in ... the mysterious disease. , When we swallow, a sphincter in ...
(Date:7/28/2014)... the U.S. Food and Drug Administration (FDA) for other ... pathogens inside human cells, including those that cause Legionnaires, ... in mBio , the online open-access journal of ... of identifying non-antibiotic drugs that could one day help ... on the list inhibit the growth of at least ...
(Date:7/28/2014)... researchers led by the University of Arizona has sequenced ... information will enhance scientists, and agriculturalists, understanding of the ... the development of new rice varieties that are better ... solve global hunger challenges. , The paper, "The genome ... evidence for independent domestication," was published online in ...
Breaking Biology News(10 mins):Mysterious esophagus disease is autoimmune after all 2New route to identify drugs that can fight bacterial infections 2Generating a genome to feed the world: UA-led team sequences African rice 2Generating a genome to feed the world: UA-led team sequences African rice 3Generating a genome to feed the world: UA-led team sequences African rice 4
... Cowman has won the Mahathir Science Award in Tropical ... the Academy of Sciences Malaysia, in recognition of his ... Foundation chairman Tun Ahmad Sarji Abdul Hamid made the ... to the global malaria research effort, leading studies into ...
... November 7, 2013 The knowledge and skills required to ... unavailable to those living with financial limitations. Competing demands ... achieving better diets. However, two researchers at the ... at the effects that three educational sessions might have ...
... associated with hydrocarbon extraction can negatively affect aquatic ... in the open-access journal PLOS ONE ... and other institutions. Hydrocarbons are a primary ... exploration and extraction are profitable enterprises, hydrocarbons contribute ...
Cached Biology News:Professor Alan Cowman wins Malaysian science award 23 'hands on' nutrition classes -- Enough to impact health behaviors in lower income women 2Drilling for hydrocarbons can impact aquatic life 2
... smallest electronic pressure controller available measuring 26 ... this unit specifically for the analytical instrumentation ... carrier gas flow control, microfluidic flow control, ... focusing, the OEM-EPC offers external pressure sensor ...
... Stroke Thrust Slide is designed for heavy ... are limited and substantial side-loading is present. ... provide millions of trouble-free cycles even in ... bushings or recirculating ball bearings , Optional ...
... offered in several versions. The Captiva 0.2 ... are ideal to prepare precipitated protein samples ... and necessary to prevent clogging of expensive ... fiber and 20 um polypropylene filter plates ...
... CyScribe Post-Labeling Kit with CyScribe GFX ... generation and purification of Cy3- and ... for complete cDNA labeling and purification.Flexible ... for performing labeling reactions with either ...
Biology Products: